View Future GrowthSynCore BiotechnologyLtd 과거 순이익 실적과거 기준 점검 0/6SynCore BiotechnologyLtd은 연평균 52.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 9.9%의 비율로 증가했습니다. 매출은 연평균 21.9%의 비율로 증가했습니다.핵심 정보52.81%순이익 성장률55.07%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률18.53%매출 성장률21.88%자기자본이익률-19.37%순이익률-162.25%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 16First quarter 2026 earnings released: NT$0.37 loss per share (vs NT$0.39 loss in 1Q 2025)First quarter 2026 results: NT$0.37 loss per share (improved from NT$0.39 loss in 1Q 2025). Revenue: NT$6.12m (up 14% from 1Q 2025). Net loss: NT$13.0m (loss narrowed 5.0% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 14Full year 2025 earnings released: NT$1.30 loss per share (vs NT$1.54 loss in FY 2024)Full year 2025 results: NT$1.30 loss per share (improved from NT$1.54 loss in FY 2024). Revenue: NT$27.0m (up 16% from FY 2024). Net loss: NT$45.8m (loss narrowed 16% from FY 2024). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 19Third quarter 2025 earnings released: NT$0.23 loss per share (vs NT$0.41 loss in 3Q 2024)Third quarter 2025 results: NT$0.23 loss per share (improved from NT$0.41 loss in 3Q 2024). Revenue: NT$6.47m (up 22% from 3Q 2024). Net loss: NT$8.04m (loss narrowed 44% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.33 loss per share (vs NT$0.38 loss in 2Q 2024)Second quarter 2025 results: NT$0.33 loss per share (improved from NT$0.38 loss in 2Q 2024). Revenue: NT$7.82m (up 10% from 2Q 2024). Net loss: NT$11.7m (loss narrowed 13% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2025 earnings released: NT$0.39 loss per share (vs NT$0.38 loss in 1Q 2024)First quarter 2025 results: NT$0.39 loss per share (further deteriorated from NT$0.38 loss in 1Q 2024). Revenue: NT$5.39m (up 23% from 1Q 2024). Net loss: NT$13.7m (loss widened 2.1% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 18Second quarter 2024 earnings released: NT$0.38 loss per share (vs NT$0.86 loss in 2Q 2023)Second quarter 2024 results: NT$0.38 loss per share (improved from NT$0.86 loss in 2Q 2023). Net loss: NT$13.5m (loss narrowed 49% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesReported Earnings • May 16First quarter 2026 earnings released: NT$0.37 loss per share (vs NT$0.39 loss in 1Q 2025)First quarter 2026 results: NT$0.37 loss per share (improved from NT$0.39 loss in 1Q 2025). Revenue: NT$6.12m (up 14% from 1Q 2025). Net loss: NT$13.0m (loss narrowed 5.0% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 14Full year 2025 earnings released: NT$1.30 loss per share (vs NT$1.54 loss in FY 2024)Full year 2025 results: NT$1.30 loss per share (improved from NT$1.54 loss in FY 2024). Revenue: NT$27.0m (up 16% from FY 2024). Net loss: NT$45.8m (loss narrowed 16% from FY 2024). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.공시 • Mar 11SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 17, 2026SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 17, 2026. Location: no,95, hsin liao rd., chung shan ts`u, dongshan township, yilan county TaiwanReported Earnings • Nov 19Third quarter 2025 earnings released: NT$0.23 loss per share (vs NT$0.41 loss in 3Q 2024)Third quarter 2025 results: NT$0.23 loss per share (improved from NT$0.41 loss in 3Q 2024). Revenue: NT$6.47m (up 22% from 3Q 2024). Net loss: NT$8.04m (loss narrowed 44% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.33 loss per share (vs NT$0.38 loss in 2Q 2024)Second quarter 2025 results: NT$0.33 loss per share (improved from NT$0.38 loss in 2Q 2024). Revenue: NT$7.82m (up 10% from 2Q 2024). Net loss: NT$11.7m (loss narrowed 13% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2025 earnings released: NT$0.39 loss per share (vs NT$0.38 loss in 1Q 2024)First quarter 2025 results: NT$0.39 loss per share (further deteriorated from NT$0.38 loss in 1Q 2024). Revenue: NT$5.39m (up 23% from 1Q 2024). Net loss: NT$13.7m (loss widened 2.1% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.공시 • Feb 27SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 20, 2025SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 20, 2025. Location: no,95, hsin liao rd., chung shan ts`u, dongshan township, yilan county TaiwanReported Earnings • Aug 18Second quarter 2024 earnings released: NT$0.38 loss per share (vs NT$0.86 loss in 2Q 2023)Second quarter 2024 results: NT$0.38 loss per share (improved from NT$0.86 loss in 2Q 2023). Net loss: NT$13.5m (loss narrowed 49% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.New Risk • Apr 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$20m revenue, or US$631k). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (NT$1.95b market cap, or US$61.0m).공시 • Mar 27SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 18, 2024SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 18, 2024.Reported Earnings • Mar 21Full year 2023 earnings released: NT$1.19 loss per share (vs NT$6.14 loss in FY 2022)Full year 2023 results: NT$1.19 loss per share (improved from NT$6.14 loss in FY 2022). Net loss: NT$38.2m (loss narrowed 80% from FY 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.New Risk • Nov 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$18m revenue, or US$555k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (NT$1.24b market cap, or US$38.8m).New Risk • Jul 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 274% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (274% increase in shares outstanding). Revenue is less than US$1m (NT$16m revenue, or US$520k).Reported Earnings • Mar 09Full year 2022 earnings released: NT$1.64 loss per share (vs NT$4.04 loss in FY 2021)Full year 2022 results: NT$1.64 loss per share (improved from NT$4.04 loss in FY 2021). Net loss: NT$188.7m (loss narrowed 59% from FY 2021). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Fu-Hsing Chang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 16Second quarter 2022 earnings released: NT$0.30 loss per share (vs NT$0.77 loss in 2Q 2021)Second quarter 2022 results: NT$0.30 loss per share (up from NT$0.77 loss in 2Q 2021). Net loss: NT$34.0m (loss narrowed 62% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Fu-Hsing Chang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 13Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: NT$4.04 loss per share (down from NT$3.83 loss in FY 2020). Net loss: NT$458.6m (loss widened 15% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year.Reported Earnings • Nov 15Third quarter 2021 earnings released: NT$1.90 loss per share (vs NT$0.96 loss in 3Q 2020)Third quarter 2021 results: Net loss: NT$218.7m (loss widened 114% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 13Second quarter 2021 earnings released: NT$0.77 loss per share (vs NT$1.08 loss in 2Q 2020)Second quarter 2021 results: Net loss: NT$88.2m (loss narrowed 20% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 16First quarter 2021 earnings released: NT$0.65 loss per share (vs NT$0.87 loss in 1Q 2020)First quarter 2021 results: Net loss: NT$71.6m (loss narrowed 15% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.Reported Earnings • Mar 24Full year 2020 earnings released: NT$3.83 loss per share (vs NT$4.54 loss in FY 2019)Full year 2020 results: Net loss: NT$398.9m (loss narrowed 2.4% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.분석 기사 • Mar 01Health Check: How Prudently Does SynCore BiotechnologyLtd (GTSM:4192) Use Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Is New 90 Day High Low • Feb 23New 90-day high: NT$54.30The company is up 11% from its price of NT$48.70 on 25 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.Is New 90 Day High Low • Jan 29New 90-day low: NT$39.95The company is down 17% from its price of NT$48.30 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 16% over the same period.Is New 90 Day High Low • Jan 11New 90-day low: NT$44.10The company is down 21% from its price of NT$55.90 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 15% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.96 loss per shareThird quarter 2020 results: Net loss: NT$102.0m (loss narrowed 7.9% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Oct 31New 90-day low: NT$48.30The company is down 33% from its price of NT$72.20 on 31 July 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.Is New 90 Day High Low • Oct 08New 90-day low: NT$58.20The company is down 58% from its price of NT$137 on 10 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 25% over the same period.매출 및 비용 세부 내역SynCore BiotechnologyLtd가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TPEX:4192 매출, 비용 및 순이익 (TWD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2628-45442431 Dec 2527-46442530 Sep 2526-46432530 Jun 2525-53432631 Mar 2524-55442731 Dec 2423-54422830 Sep 2423042-3030 Jun 2423-1542-1631 Mar 2421-2841-531 Dec 2320-3842430 Sep 2319-1624213030 Jun 2318-1634212731 Mar 2316-1704114131 Dec 2216-1894315730 Sep 2214-1874315530 Jun 2211-3754334831 Mar 229-4294239131 Dec 217-4593942330 Sep 2110-4813844430 Jun 2112-3643832531 Mar 2113-3863835231 Dec 2013-3993936330 Sep 2010-4094037530 Jun 208-4174138531 Mar 209-4304339831 Dec 1913-4094538030 Sep 1913-3894536230 Jun 1913-3594732931 Mar 1912-3064727631 Dec 188-2944825830 Sep 188-2704622930 Jun 188-2534421631 Mar 188-2474421231 Dec 178-2584022430 Sep 178-1863922830 Jun 178-1773921931 Mar 177-1763722331 Dec 167-1623820830 Sep 167-1853917930 Jun 167-2014419031 Mar 1616-1794716831 Dec 1515-1824817030 Sep 1515-2235820430 Jun 1515-22363196양질의 수익: 4192 은(는) 현재 수익성이 없습니다.이익 마진 증가: 4192는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 4192는 수익성이 없지만 지난 5년 동안 연평균 52.8%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 4192의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 4192은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 4192는 현재 수익성이 없으므로 자본 수익률이 음수(-19.37%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 09:12종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SynCore Biotechnology Co.,Ltd는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 16First quarter 2026 earnings released: NT$0.37 loss per share (vs NT$0.39 loss in 1Q 2025)First quarter 2026 results: NT$0.37 loss per share (improved from NT$0.39 loss in 1Q 2025). Revenue: NT$6.12m (up 14% from 1Q 2025). Net loss: NT$13.0m (loss narrowed 5.0% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 14Full year 2025 earnings released: NT$1.30 loss per share (vs NT$1.54 loss in FY 2024)Full year 2025 results: NT$1.30 loss per share (improved from NT$1.54 loss in FY 2024). Revenue: NT$27.0m (up 16% from FY 2024). Net loss: NT$45.8m (loss narrowed 16% from FY 2024). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 19Third quarter 2025 earnings released: NT$0.23 loss per share (vs NT$0.41 loss in 3Q 2024)Third quarter 2025 results: NT$0.23 loss per share (improved from NT$0.41 loss in 3Q 2024). Revenue: NT$6.47m (up 22% from 3Q 2024). Net loss: NT$8.04m (loss narrowed 44% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.33 loss per share (vs NT$0.38 loss in 2Q 2024)Second quarter 2025 results: NT$0.33 loss per share (improved from NT$0.38 loss in 2Q 2024). Revenue: NT$7.82m (up 10% from 2Q 2024). Net loss: NT$11.7m (loss narrowed 13% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2025 earnings released: NT$0.39 loss per share (vs NT$0.38 loss in 1Q 2024)First quarter 2025 results: NT$0.39 loss per share (further deteriorated from NT$0.38 loss in 1Q 2024). Revenue: NT$5.39m (up 23% from 1Q 2024). Net loss: NT$13.7m (loss widened 2.1% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 18Second quarter 2024 earnings released: NT$0.38 loss per share (vs NT$0.86 loss in 2Q 2023)Second quarter 2024 results: NT$0.38 loss per share (improved from NT$0.86 loss in 2Q 2023). Net loss: NT$13.5m (loss narrowed 49% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
Reported Earnings • May 16First quarter 2026 earnings released: NT$0.37 loss per share (vs NT$0.39 loss in 1Q 2025)First quarter 2026 results: NT$0.37 loss per share (improved from NT$0.39 loss in 1Q 2025). Revenue: NT$6.12m (up 14% from 1Q 2025). Net loss: NT$13.0m (loss narrowed 5.0% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 14Full year 2025 earnings released: NT$1.30 loss per share (vs NT$1.54 loss in FY 2024)Full year 2025 results: NT$1.30 loss per share (improved from NT$1.54 loss in FY 2024). Revenue: NT$27.0m (up 16% from FY 2024). Net loss: NT$45.8m (loss narrowed 16% from FY 2024). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
공시 • Mar 11SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 17, 2026SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 17, 2026. Location: no,95, hsin liao rd., chung shan ts`u, dongshan township, yilan county Taiwan
Reported Earnings • Nov 19Third quarter 2025 earnings released: NT$0.23 loss per share (vs NT$0.41 loss in 3Q 2024)Third quarter 2025 results: NT$0.23 loss per share (improved from NT$0.41 loss in 3Q 2024). Revenue: NT$6.47m (up 22% from 3Q 2024). Net loss: NT$8.04m (loss narrowed 44% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.33 loss per share (vs NT$0.38 loss in 2Q 2024)Second quarter 2025 results: NT$0.33 loss per share (improved from NT$0.38 loss in 2Q 2024). Revenue: NT$7.82m (up 10% from 2Q 2024). Net loss: NT$11.7m (loss narrowed 13% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2025 earnings released: NT$0.39 loss per share (vs NT$0.38 loss in 1Q 2024)First quarter 2025 results: NT$0.39 loss per share (further deteriorated from NT$0.38 loss in 1Q 2024). Revenue: NT$5.39m (up 23% from 1Q 2024). Net loss: NT$13.7m (loss widened 2.1% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
공시 • Feb 27SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 20, 2025SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 20, 2025. Location: no,95, hsin liao rd., chung shan ts`u, dongshan township, yilan county Taiwan
Reported Earnings • Aug 18Second quarter 2024 earnings released: NT$0.38 loss per share (vs NT$0.86 loss in 2Q 2023)Second quarter 2024 results: NT$0.38 loss per share (improved from NT$0.86 loss in 2Q 2023). Net loss: NT$13.5m (loss narrowed 49% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
New Risk • Apr 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$20m revenue, or US$631k). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (NT$1.95b market cap, or US$61.0m).
공시 • Mar 27SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 18, 2024SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 18, 2024.
Reported Earnings • Mar 21Full year 2023 earnings released: NT$1.19 loss per share (vs NT$6.14 loss in FY 2022)Full year 2023 results: NT$1.19 loss per share (improved from NT$6.14 loss in FY 2022). Net loss: NT$38.2m (loss narrowed 80% from FY 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
New Risk • Nov 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$18m revenue, or US$555k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (NT$1.24b market cap, or US$38.8m).
New Risk • Jul 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 274% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (274% increase in shares outstanding). Revenue is less than US$1m (NT$16m revenue, or US$520k).
Reported Earnings • Mar 09Full year 2022 earnings released: NT$1.64 loss per share (vs NT$4.04 loss in FY 2021)Full year 2022 results: NT$1.64 loss per share (improved from NT$4.04 loss in FY 2021). Net loss: NT$188.7m (loss narrowed 59% from FY 2021). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Fu-Hsing Chang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 16Second quarter 2022 earnings released: NT$0.30 loss per share (vs NT$0.77 loss in 2Q 2021)Second quarter 2022 results: NT$0.30 loss per share (up from NT$0.77 loss in 2Q 2021). Net loss: NT$34.0m (loss narrowed 62% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Fu-Hsing Chang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 13Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: NT$4.04 loss per share (down from NT$3.83 loss in FY 2020). Net loss: NT$458.6m (loss widened 15% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year.
Reported Earnings • Nov 15Third quarter 2021 earnings released: NT$1.90 loss per share (vs NT$0.96 loss in 3Q 2020)Third quarter 2021 results: Net loss: NT$218.7m (loss widened 114% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 13Second quarter 2021 earnings released: NT$0.77 loss per share (vs NT$1.08 loss in 2Q 2020)Second quarter 2021 results: Net loss: NT$88.2m (loss narrowed 20% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 16First quarter 2021 earnings released: NT$0.65 loss per share (vs NT$0.87 loss in 1Q 2020)First quarter 2021 results: Net loss: NT$71.6m (loss narrowed 15% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 24Full year 2020 earnings released: NT$3.83 loss per share (vs NT$4.54 loss in FY 2019)Full year 2020 results: Net loss: NT$398.9m (loss narrowed 2.4% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
분석 기사 • Mar 01Health Check: How Prudently Does SynCore BiotechnologyLtd (GTSM:4192) Use Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Is New 90 Day High Low • Feb 23New 90-day high: NT$54.30The company is up 11% from its price of NT$48.70 on 25 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.
Is New 90 Day High Low • Jan 29New 90-day low: NT$39.95The company is down 17% from its price of NT$48.30 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 16% over the same period.
Is New 90 Day High Low • Jan 11New 90-day low: NT$44.10The company is down 21% from its price of NT$55.90 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 15% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.96 loss per shareThird quarter 2020 results: Net loss: NT$102.0m (loss narrowed 7.9% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Oct 31New 90-day low: NT$48.30The company is down 33% from its price of NT$72.20 on 31 July 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Oct 08New 90-day low: NT$58.20The company is down 58% from its price of NT$137 on 10 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 25% over the same period.